NetworkNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Targets Several Indications with Wide-ranging Product Pipeline
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) that currently has numerous pharmaceutical and nutraceutical products in its development pipeline. An article discussing the company reads: “Pivot has a number of products in its pipeline that are in various stages of development. These target therapies for pain, inflammation, dermatology, eye disease and cancer supportive care. PGS-N005 is a cannabidiol (CBD)-based topical cream to treat female sexual dysfunction, a disorder that is estimated to affect up to 63 percent of women in the United States (http://nnw.fm/QoAH2). The market for female sexual dysfunction disorder therapies is estimated to be more than $4 billion.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) that currently has numerous pharmaceutical and nutraceutical products in its development pipeline. An article discussing the company reads: “Pivot has a number of products in its pipeline that are in various stages of development. These target therapies for pain, inflammation, dermatology, eye disease and cancer supportive care. PGS-N005 is a cannabidiol (CBD)-based topical cream to treat female sexual dysfunction, a disorder that is estimated to affect up to 63 percent of women in the United States (http://nnw.fm/QoAH2). The market for female sexual dysfunction disorder therapies is estimated to be more than $4 billion.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer